top of page

BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region

  • blonca9
  • Nov 4, 2024
  • 1 min read

Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as atrogi, empros pharma, and xspray.



Brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page